An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 409-417

  Friberg, L E ^a   Vermeulen, A M ^b   Petersson, K J F ^a   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; PROLACTIN; RISPERIDONE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; DOPAMINE RELEASE; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG POTENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SUSTAINED RELEASE FORMULATION;

DRUG INTERACTIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MODELS, BIOLOGICAL; PROLACTIN; PYRIMIDINES; RISPERIDONE;

EID: 62649083604     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.234     Document Type: Article

References (34)

1. Petty, R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res. 35 (suppl.), S67-S73 (1999).
2. Hamner, M.B. & Arana, G.W. Hyperprolactinaemia in antipsychotic-treated patients. Guidelines for avoidance and management. CNS Drugs 109, 210-222 (1998).
3. Kapur, S., Langlois, X., Vinken, P., Megens, A.A., De Coster, R. & Andrews, J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 302, 1129-1134 (2002).
4. Movin-Osswald, G. & Hammarlund-Udenaes, M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J. Pharmacol. Exp. Ther. 274, 921-927 (1995).
5. Bagli, M. et al. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J. Pharmacol. Exp. Ther. 291, 547-554 (1999).
6. Francheteau, P., Steimer, J.L., Dubray, C. & Lavene, D. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J. Pharmacokinet. Biopharm. 19, 287-309 (1991).
7. Veldhuis, J.D., Iranmanesh, A., Johnson, M.L. & Lizarralde, G. Twenty-four-hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J. Clin. Endocrinol. Metab. 71, 1616-1623 (1990).
8. Leysen, J.E., Janssen, P.M., Megens, A.A. & Schotte, A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55 (suppl.), 5-12 (1994).
9. Leysen, J.E. et al. Schizophrenia, an integrated view. In Alfred Benzon Symposium 38 (eds. Fog, R., Gerlach, J. & Hemningsen, R.)344-356 (Munksgard, Copenhagen, Denmark, 1995).
10. Schotte, A. et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124, 57-73 (1996).
11. Huang, M.L. et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54, 257-268 (1993).
12. Hempel, G., Karlsson, M.O., de Alwis, D.P., Toublanc, N., McNay, J. & Schaefer, H.G. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin. Pharmacol. Ther. 64, 622-635 (1998).
13. Piotrovsky, V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7, E609-E624 (2005).
14. Gardmark, M., Karlsson, M.O., Jonsson, F. & Hammarlund-Udenaes, M. Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling. J. Pharm. Sci. 87, 813-820 (1998).
15. Zhu, B.T. The competitive and noncompetitive antagonism of receptor-mediated drug actions in the presence of spare receptors. J. Pharmacol. Toxicol. Methods 29, 85-91 (1993).
16. Gibiansky, L. Precision of parameter estimates: covariance ($COV) step versus bootstrap procedure. Copenhagen, Denmark, 13-15 June 2007, p 16, Abstr 1106. 〈http://www.page-meeting.org/?abstract=1106〉.
17. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007).
18. Veldman, R.G., Frolich, M., Pincus, S.M., Veldhuis, J.D. & Roelfsema, F. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. J. Clin. Endocrinol. Metab. 86, 1562-1567 (2001).
19. Frantz, A.G. Prolactin. N. Engl. J. Med. 298, 201-207 (1978).
20. Rao, M.L. et al. Hyperdopaminergia in schizophreniform psychosis: a chronobiological study. Psychiatry Res. 47, 187-203 (1993).
21. Rao, M.L. et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol. Psychiatry 35, 151-163 (1994).
22. Cooper, D.S., Ridgway, E.C., Kliman, B., Kjellberg, R.N. & Maloof, F. Metabolic clearance and production rates of prolactin in man. J. Clin. Invest. 64, 1669-1680 (1979).
23. Nathan, R.S. et al. A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Psychopharmacology (Berl.) 80, 46-49 (1983).
24. Eberhard, J., Lindstrom, E., Holstad, M. & Levander, S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr. Scand. 115, 268-276 (2007).
25. Haddad, P.M. & Wieck, A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291-2314 (2004).
26. Petersson, K., Friberg, L.E. & Karlsson, M.O. Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM VI. Marseille, France, 18-20 June 2008, p 17, Abstr 1361. 〈http://www.page-meeting.org/default.asp?abstract=1361〉.
27. Keks, N.A., Copolov, D.L. & Singh, B.S. Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am. J. Psychiatry 144, 1335-1337 (1987).
28. Vermeulen, A., Piotrovsky, V. & Ludwig, E.A. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J. Pharmacokinet. Pharmacodyn. 34, 183-206 (2007).
29. Halbreich, U. & Kahn, L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 9, 344-353 (2003).
30. Kinon, B.J., Gilmore, J.A., Liu, H. & Halbreich, U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (suppl 2.), 55-68 (2003).
31. Mandema, J.W., Verotta, D. & Sheiner, L.B. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20, 511-528 (1992).
32. Jonsson, E.N. & Karlsson, M.O. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
33. Beal, S.L., Sheiner, L.B. & Boeckmann, A.J. NONMEM Users Guides (Icon Development Solutions, Ellicott City, MD, 1989-2006).
34. Wahlby, U., Jonsson, E.N. & Karlsson, M.O. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28, 231-252 (2001).